Philadelphia chromosome-positive acute lymphoblastic leukemia: exploring microRNA-based strategies to improve outcomes
Authors:
- Setare KheyrandishSKSetare Kheyrandish
- Niloofar PilehvariNPNiloofar Pilehvari
- Amirhossein RastgarARAmirhossein Rastgar
- Mehdi Allah Bakhshian-FarsaniMBMehdi Allah Bakhshian-Farsani
- Bahram ChahardouliBCBahram Chahardouli
- Zahra NazariZNZahra Nazari
- Shahrbano RostamiSRShahrbano Rostami
- Saeed MohammadiSMSaeed Mohammadi
- Ahmad GharehbaghianAGAhmad Gharehbaghian
- 18 November 2025
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 94
Abstract
Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR::ABL1 fusion gene resulting from the translocation t(9;22). This type of leukemia represents a biologically and clinically distinct subset of ALL, known for its aggressive nature and comparatively poor prognosis among hematologic malignancies. Although the advent of tyrosine kinase inhibitors (TKIs) has converted the therapeutic view and fulfilled short-term outcomes, resistant responses remain limited, and disease relapse, often due to BCR::ABL1 kinase domain mutations or activation of alternative signaling pathways, continues to impede long-term success. Recent findings emphasizes the essential involvement of microRNAs in leukemogenesis, TKI resistance, and the advancement of Ph+ ALL. Importantly, miR-17∼92 cluster members (such as miR-17, miR-18a, miR-20a) can prompt apoptosis by direct suppression of BCL2 in BCR::ABL1 positive cells. Moreover, epigenetic silencing of miR-203 enhances BCR::ABL1 expression, further contributing to TKI resistance. These small regulatory RNAs consequently act for promising candidates both as therapeutic targets and as prognostic biomarkers, with the potential to fill treatment gaps that persist even in the TKI era.Keywords
This publication has 70 references indexed in Scilit:
- Critical roles of the miR-17∼92 family in thymocyte development, leukemogenesis, and autoimmunityCell Reports, 2024
- The miR‐17‐92 cluster in cardiac health and diseaseBirth Defects Research, 2023
- The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemiaBest Practice & Research Clinical Haematology, 2023
- International Consensus Classification of acute lymphoblastic leukemia/lymphomaVirchows Archiv, 2022
- MicroRNA‐99 family in cancer and immunityWIREs RNA, 2020
- Roles and clinical implications of microRNAs in acute lymphoblastic leukemiaJournal of Cellular Physiology, 2017
- MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migrationBiomedicine & Pharmacotherapy, 2015
- Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment OptionsCurrent Oncology Reports, 2012
- Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaCurrent Hematologic Malignancy Reports, 2011
- The Endothelial-Specific MicroRNA miR-126 Governs Vascular Integrity and AngiogenesisDevelopmental Cell, 2008